

Original article

Molecular analysis of Malaysian Chinese D- donors: a single centre experience

Tay Za Kyaw, Jayaranee A.S. Maniam, Veera Sekaran Nadarajan, Hemalatha Shanmugam

Department of Pathology, Faculty of Medicine, University Malaya, Kuala Lumpur 50603, Malaysia

Background: The Rh blood group system is highly polymorphic and next to the ABO system is the most clinically significant in transfusion medicine. The frequency of D- phenotypes and the underlying molecular genetics vary widely in different populations.

Objectives: We determined the prevalence of different D- phenotypes among Malaysian blood donors in a tertiary medical centre and identified the molecular basis of Chinese D- donors in this population.

Materials and methods: A total of 146 D- Chinese donors with various Rh phenotypes were identified from review of blood donor records between January 2003 and September 2008. Fresh blood samples from 36 of these donors were obtained and further characterized by PCR-SSP to determine the molecular basis of these D- individuals.

Results: A total of 86,620 blood donor records were reviewed. Of these 911 were D-, consisting of 483 Indians, 189 Malays and 146 Chinese. The ccee phenotype was the most common among D- individuals with a prevalence of 91.51% (442/483) in Indians, 74.60% (141/189) in Malays and 55.48% (81/146) in Chinese. D- phenotypes with C and/or E antigens were most common in Chinese {44.52% (65/146)}. In the molecular analysis of the 36 D- Chinese donor samples, 19 samples with ccee phenotype and 5/17 of samples with Ccee phenotype showed no detectable *RHD* gene. The remaining 12/17 Ccee samples had intact *RHD* genes with *RHD* (K409K) mutation. **Conclusion:** In our donor population, we found a wide variation in the incidence of D- as well as the distribution of various D- phenotypes among the three major ethnic groups. A significant number of D- Chinese donors with Ccee phenotype were found to be DEL with *RHD* (K409K) mutation. DEL red cells are known to cause anti-D alloimmunization. Therefore, in clinical practice, it is important to exclude DEL RBCs from D- donor pools.

Keywords: Chinese D- donors, DEL variant, Malaysian blood donors, molecular genotyping, RhD-negative phenotypes

The Rh blood group is the most complex and polymorphic of all human blood group systems, consisting of at least 46 different antigens. Next to the ABO blood group system, it is the most clinically significant in transfusion medicine [1, 2]. The D antigen is a potent immunogen and is responsible for most of the clinical problems, such as haemolytic transfusion reactions (HTR) and haemolytic disease of the foetus and newborn (HDFN). The Rh antigens are encoded by two genes on the short arm of chromosome 1: the *RHD* and *RHCE* genes. *RHD*

encodes the RhD protein which carries the D antigen whereas *RHCE* encodes RhCE protein which carries the CE antigens in various combinations (ce, Ce, cE, or CE) [3-6]. These two genes are highly homologous, having 10 exons each. However, the encoded proteins differ by 32 to 35 amino acids [7]. This degree of difference explains why exposure to D antigen can result in a potent immune response in D-individuals [7].

Wide racial differences are recognized not only in the frequency of RhD-negative (D-) phenotypes but also in the molecular basis of D- phenotypes [8]. The frequent cause of D- in Europeans is the deletion of the entire *RHD* gene [9] whereas D- phenotypes in Africans and Asians are caused by silent or inactive *RHD* genes due to the presence of various *RHD* alleles [7].

Correspondence to: Dr. Kyaw Tay Za, Department of Pathology, Faculty of Medicine, University Malaya, Kuala Lumpur 50603, Malaysia. E-mail: kyawtayza79@gmail.com

Many Asians who type as D- by routine serologic typing have been found to be D-elute (DEL) [7]. The DEL phenotype is an extreme form of weak D which is only detectable serologically by adsorption and elution techniques [10, 11]. Compared to a normal D antigen which consists of about 30,000 D sites per cell, the number of D sites on a DEL RBC is about 20-40 per cell [12]. In China and Japan, approximately 10-30% of apparent D- individuals are DEL phenotypes whereas its incidence is very low in Europeans [10, 13-17]. DEL phenotypes are caused by many genetic mechanisms. *RHD*(K409K) is the most frequent allele among *DEL* variants, occurring with a reported frequency of 1:110 and 1:9091 in Chinese and German populations respectively [13, 15].

The Malaysian blood donor population is composed of three major ethnic groups (Malay, Chinese and Indian) and other minor ethnic groups (e.g. native people from East Malaysia). As the donor population is quite heterogeneous, we expect the distribution of Rh phenotypes and genotypes to vary as well. The aims of this study are; 1) to determine the prevalence of different D- phenotypes among Malaysian blood donors in a tertiary medical centre and 2) to identify the molecular basis of Chinese D- donors in this population.

Materials and methods

Sample selection and collection

We reviewed blood donor records of our centre between January 2003 and September 2008 using the laboratory information system. During this period, D antigen status of blood donors was determined with a monoclonal anti-D (Clones TH-28, IgM, and MS-26, IgG; Diamed, Cressier sur Morat, Switzerland) using the tube typing method. When no agglutination was detected, indirect antiglobulin test was performed to exclude a weak D antigen. Subsequently Rh phenotyping for D, C, c, E and e antigens was performed for all D- samples using column agglutination technique (Diamed, Cressier sur Morat, Switzerland) as per manufacturer's recommendations. Adsorption-elution tests were not routinely performed for D- donors.

As there was no archived blood samples of donors, D- Chinese donors who donated blood during this period were invited to give blood samples for this study. Out of 126 Chinese D-donors with ccee and Ccee phenotypes, 36 donors volunteered to give blood samples, 19 with ccee phenotype and 17 with Ccee

phenotype. Blood was collected into K²-Ethylene diaminetetraacetic acid (EDTA) tubes (Becton-Dickinson, Franklin Lakes, NJ, USA). This study was approved by the Ethics Committee of University Malaya Medical Centre.

PCR-SSP genotyping for *RHD* and *RHCE* genes and *RHD* variants

Genomic DNA extraction was done within 1 week of sample collection using a spin protocol by QIAamp DNA Blood Mini Kit (Qiagen®, Hilden, Germany) according to manufacturer's instructions. Isolated DNA had a purity index (extinction ratio OD₂₆₀/OD₂₈₀) between 1.5 and 2.0 [measured by the NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, USA)].

Polymerase Chain Reaction- Sequence Specific Primers (PCR-SSP) genotyping was performed using the BAGene RH-TYPE kit (BAG Health Care, Lich, Germany) according to manufacturer's instructions. Each BAGene RH-TYPE kit consists of 10 tests and each test has 13 reactions. Reactions 1 and 2 consist of multiplex-PCR reactions targeting intron 4 and exons 4/7 of the *RHD* gene in reaction 1 and intron 7 of the *RHD* gene in reaction 2. The second reaction also has primers for detection of *RHD* (W16X) and *RHD* pseudo gene. The primers in reactions 3 to 8 are designed to detect *RHD* exon 4 for non *RHD* pseudogene sequence, intron 9 for non *RHD* (K409K) sequence, *RHD* (K409K) mutation, *RHD* (M295I) mutation, *RHD* (IVS 3+1G>A) mutation and Cde^s respectively. Promoter sequence, exon 1, intron 2, exon 2, and exon 5 of *RHCE* gene were analyzed in reactions 9 to 13 to detect the presence of C, c, e, E, or C^w alleles. This PCR strategy can also detect other *RHD* variants such as *RHD-CE* (8-9)-D, *RHD-CE* (3-7)-D, D VI, and D IV type3. Human growth hormone (HGH) gene (generating a band of 434 bp) was used as an internal control in all reactions except in reaction 2. In reaction 2, the control band was of 659 bp (specific for genomic sequence of chromosome 1, 90,000 bp 5' of the Rhesus box).

PCR master-mix solutions were prepared for each sample and consisted of 10-20 µl of the template DNA (volume adjusted according to the DNA concentration), 124-134 µl of H₂O, 16 µl of PCR buffer and 1.3 µl of Taq polymerase (Qiagen, Hilden, Germany) resulting in a final volume of 160 µl. 10 µl of this prepared master mix was aliquoted into the respective reaction tubes which were coated with

specific primers. PCR amplification was carried out in the Eppendorf MasterCycler® Gradient (Eppendorf, Hamburg, Germany). Thermocycling conditions were applied according to manufacturer's instructions. PCR products were visualized in 2% agarose gel.

Results

Rh serotyping findings

Between the period of January 2003 and September 2008, a total of 86,620 blood donors donated blood at our centre. Of these donors, 44.56% (38,599) were Chinese, 41.34% (35,809) were Malays and 10.12% (8,769) were Indians. The remaining 3.98% (3,443) consisted of donors from minor ethnic groups and foreigners. 911 blood donors during this period were D-. The incidence of D- was found to be 5.51% (483/8,769) in Indians, 0.38% (146/38,599) in Chinese and 0.53% (189/35,809) in Malays. The commonest D- phenotype was ccee. This was observed in 91.51% of Indians (442/483), 74.60% of Malays (141/189) and 55.48% of Chinese (81/146) and 92.47% of donors of other ethnic groups and foreigners (86/93). D- phenotypes with C and/or E antigens (such as

Ccee, CCee, CcEe and ccEe phenotypes) were noted in 44.52% (65/146) of Chinese, 25.40% (48/189) of Malays, 8.49% (41/483) of Indians and 7.53% (7/93) of donors of other ethnic groups and foreigners as shown in **Table 1**.

PCR-SSP findings

Genomic DNA of the 36 Rh-D negative Chinese donors was subjected to PCR-SSP. In 24 D- samples, no PCR products for *RHD* sequences or other *RHD* mutations were obtained. These samples were placed in group I. Of these 24 samples, 19 were of ccee phenotype and five were of Ccee phenotype. In the remaining 12 samples, *RHD* sequences were observed and these were placed in group II. All these 12 samples were of Ccee phenotype and have *RHD* (K409K) mutation. The PCR results for C, c, E, and e alleles of *RHCE* gene were in complete concordance with serological results in all 36 donors of group I and II. PCR results from groups I and II are summarized in **Table 2**. Gel electrophoresis depicting the above PCR reactions from both groups are illustrated in **Figure 1a, 1b, and 1c**.

Table 1. The prevalence of different Rh phenotypes among 86620 blood donors of various races.

Race	RhD+ donors	RhD- donors with different phenotypes*					Total□
		ccee	Ccee	CCee	CcEe	ccEe	
Chinese	38,453 (99.62%)	81 (0.21%)	45 (0.12%)	14 (0.04%)	2 (0.01%)	4 (0.01%)	38,599
Indian	8,286 (94.49%)	442 (5.04%)	38 (0.43%)	1 (0.01%)	0	2 (0.02%)	8,769
Malays	35,620 (99.47%)	141 (0.39%)	38 (0.11%)	5 (0.01%)	2 (0.01%)	3 (0.01%)	35,809
Others□	3,350 (97.30%)	86 (2.50%)	6 (0.17%)	1 (0.03%)	0	0	3,443
Total□	85,709 (98.95%)	750 (0.87%)	127 (0.15%)	21 (0.02%)	4 (0.005%)	9 (0.01%)	86,620

* The phenotyping of D, C, c, E and e antigens were performed for all D- donors after exclusion of weak D by indirect antiglobulin test.

□ Other donors include minor ethnic groups and foreigners.

□ Total number of donors in terms of race.

□ Total number of donors in terms of Rh phenotype.

Table 2. PCR-SSP results of 36 D- Malaysian Chinese donors of ccee and Ccee phenotypes.

Group*	Number	Phenotype	RHD and RHCE genotyping with BAGene typing kit			
			RHD Introns 4/7	RHD exons 4/7	K409K mutation	RHCE gene
I	19	ccee	-	-	-	c, e
	5	Ccee	-	-	-	C, c, and e
II	12	Ccee	+	+	+	C, c, and e

*Group I=the absence of *RHD* gene with no *RHD* K409K mutation, Group II=Intact *RHD* gene with *RHD* K409K mutation




Figure 1. Gel electrophoresis of amplified DNA products. (a) D- ccee phenotype (from Group I) with amplified products in lane 10 and lane 12 (b) D- Ccee phenotype (from Group I) with amplified products in lane 9, lane 10, and lane 12 (c) DEL with Ccee phenotype (from Group II) with amplified products in lane 1, lane 2 (390 bp product), lane 3, lane 5, lane 9, lane 10, and lane 12 (d) RhD-positive control sample with CCee phenotype with amplified products in lane 1, lane 2 (390bp product), lane 3, lane 4, lane 9, and lane 12. In all the lanes, a 434 bp fragments was amplified representing the internal control except in lane 2 where the size of internal control was 659 bp. M, 100 bp ladder marker; Lane 1, 224 bp, and 123 bp amplified PCR products for intron4/exon4 and exon 7 of *RHD*; Lane 2, 390 bp amplified products for intron 7 of *RHD*, 248 bp product for *RHD*(W16X) and 154 bp product for *RHD pseudo gene*; Lane 3, band of 140bp for non pseudo-*RHD* sequence; Lane 4, 113 bp for non *RHD*(K409K) mutation; Lane 5, 113 bp for *RHD* (K409K) mutation; Lane 6, 198 bp for *RHD* (M295I) mutation; Lane 7, 143 bp for *RHD* (IVS3+1G>A) mutation; Lane 8, 215 bp for *Cde*^s; Lanes 9-12 respectively, amplified products of different alleles of *RHCE*: 162bp for *C/C*^w; 145 bp for *c*; 157 bp for *E*; 155 bp for *e*; Lane 13, 181 bp product for *C*^w; Lane 14, water control.

Discussion

The frequency of D- phenotypes varies widely in different parts of the world and is common in Caucasians (15%) [18]. It is noted in 3 to 7% of Africans [18], 5% of Indians [19] and 0.2 - 0.4% of Chinese individuals [20]. Our study showed that the

incidence of D- among Indian and Chinese blood donors was 5.51% and 0.38% respectively which is comparable to previously published data. The incidence of D- in Malay individuals was 0.53%. There is no published data on D- incidence in this ethnic group for comparison. The ccee phenotype was the most

common among our D- donors but the distribution of this phenotype varied widely among the different races as shown in **Table 1**. D- phenotypes with C and/or E antigens (such as Ccee, CCee, ccEe and CcEe) were more frequently seen in Chinese donors (44.52%) compared to the other two races. The proportion of these phenotypes was notably lower in Malay (25.40%) and Indian (8.49%) donors. To our knowledge, there are no published data on the prevalence of various RhD- phenotypes in Malay, Chinese and Indian individuals in this region. Understanding the distribution of different D- phenotypes is important in transfusion practice within a multi-ethnic environment and for situations such as estimating the availability of compatible blood as well as evaluating the cases of HTR and HDFN.

The *RHD* gene is polymorphic in the Chinese population [8, 13, 14, 17, 21-23]. A considerable proportion of apparently D- samples in this Chinese population from China and Taiwan were DEL phenotype with intact *RHD* gene [13, 14, 17, 24, 25]. *RHD* (K409K) mutation was found to be the underlying cause of almost all cases of DEL in Asia [2, 13, 24, 26]. In this study, DEL variant was observed in 33.33% (12/36) of D- Malaysian Chinese donors. All these individuals had an intact *RHD* gene with *RHD* (K409K) mutation. Although *RHD* (K409K) mutation is usually observed in DEL, this mutation has also been reported in some weak D phenotypes [13]. As the indirect anti-globulin test is routinely performed in our D- donors, weak D phenotypes were excluded in our donors with *RHD* (K409K) mutation. Although our sample size for PCR-SSP was small, there was a strong association between D- donors with RhC+ phenotype and DEL. Nearly three-fourths of our D- donors with Ccee phenotype were DEL variant with an intact *RHD* gene and *RHD* (K409K) mutation as shown in **Table 2**. This is in concordance with previous studies done in Chinese populations in China, Hong Kong and Taiwan [13, 24, 25, 27].

Although DEL is the weakest known D positive phenotype in the Rh system, the potential danger that DEL red cells might cause a clinical transfusion reaction cannot be completely excluded. It was noted that recipients who were truly D-negative developed anti-D after transfusion with DEL red blood cells [28, 29]. Therefore, it is important to exclude DEL donors from the D- donor pool particularly in areas with high incidence of DEL. Adsorption and elution technique is the only available serological method for the

detection of DEL. This method is difficult and not feasible to be put into practice as a routine screening tool. Alternatively, molecular screening techniques can be used in D- donors particularly those with DCE haplotype for the detection of *RHD* (K409K) mutation. RhC phenotyping together with molecular screening is simple, reliable and more specific for the detection of this common mutation in D- individuals.

In a large study of 7688 D- Caucasian donors with ccee phenotype conducted by Wagner et al [15], the deletion of *RHD* gene was the major cause of D- phenotype in these individuals. *RHD* gene was not detectable in all of our Chinese donors with ccee phenotype. This is in keeping with results observed in a study in China by Ye et al [20]. In other studies where a primer targeting exon 10 was included as a part of PCR strategy in screening for D- donors, *RHD* alleles were observed in a few individuals. Nearly all of these cases had RhC+ phenotypes and most were found to have *RHD-CE* (2-9) *D2* hybrid allele [13, 23, 30]. As the primer for detection of exon 10 was not included, the presence of such hybrid alleles cannot be completely excluded in our D- donors with Ccee phenotype. However, blood donors carrying *RHD-CE* (2-9) *D2* hybrid allele may safely be overlooked because their RBC units are truly D- [31].

In conclusion, D- phenotype was found predominantly in the Indians with less than 1% noted in Malays and Chinese in our donor population. There was a wide variation in the distribution of different D- phenotypes among our three major races. Understanding the distribution of different D- phenotypes in a multi-ethnic donor population is important for good transfusion medicine practices. Moreover, this study also revealed that a significant number of our D- Chinese donors with Ccee phenotype were in fact DEL with *RHD* (K409K) mutation. DEL red cells are known to cause anti-D alloimmunization. Therefore, it is important to exclude DEL blood units from D- donor pools particularly in areas with high incidence of DEL.

Acknowledgements

The authors wish to thank all the blood donors who participated in this study. We also thank Mohd. Kamil and Mohd. Ashraf from Molecular and Genetic Analysis Laboratory, Laboratory Medicine Division, University Malaya Medical Centre for their technical assistance, Mrs. Prager, and Mr. Thomas from BAG Health Care for their helpful comments. This work

was supported by a research grant (Grant No. P0034-2009B) from University Malaya. The authors decline no relevant financial interests.

References

1. Avent ND, Reid ME. The Rh blood group system: a review. *Blood*. 2000; 95:375-87.
2. Kim JY, Kim SY, Kim AH, Yon GS, Park SS. Molecular characterization of D-Korean persons: development of a diagnostic strategy. *Transfusion*. 2005; 45:345-52.
3. Cherif-Zahar B, Bloy C, Le Van Kim C, Blanchard B, Bailly P, Hermand P, et al. Molecular cloning and protein structure of a human blood group Rh polypeptide. *Proc Natl Acad Sci U S A*. 1990; 87:6243-7.
4. Cherif-Zahar B, Mattei MG, Le Van Kim C, Bailly P, Cartron JP, Colin Y. Localization of the human Rh blood group gene structure to chromosome 1p34.3-1p36.1 region by in situ hybridization. *Hum Genet*. 1991; 86: 398-400.
5. Arce MA, Thompson ES, Wagner S, Coyne KE, Ferdman BA, Lublin DM. Molecular cloning of RhD cDNA derived from a gene present in RhD-positive, but not RhD-negative individuals. *Blood*. 1993; 82: 651-5.
6. Simsek S, de Jong CAM, Cuijpers HTM, Bleeker PMM, Westers TM, Overbeeke MAM, et al. Sequence analysis of cDNA derived from reticulocyte mRNAs coding for Rh polypeptides and demonstration of E/e and C/c polymorphism. *Vox Sang*. 1994; 67:203-9.
7. Westhoff CM. The Rh blood group system in review: A new face for the next decade. *Transfusion*. 2004; 44: 1663-73.
8. Lan JC, Chen Q, Wu DL, Ding H, Pong DB, Zhao T, et al. Genetic polymorphism of RhD-negative associated haplotypes in the Chinese. *J Hum Genet*. 2000; 45:224-7.
9. Colin Y, Cherif-Zahar B, Le Van Kim C, Raynal V, Van Huffel V, Carton JP, et al. Genetic basis of the RhD-positive and RhD-negative blood group polymorphism as determined by Southern analysis. *Blood*. 1991; 78: 2747-52.
10. Okubo Y, Yamaguchi H, Tomita T, Nagao N. A D variant, Del? *Transfusion*. 1984; 24:542.
11. Flegel WA. Molecular genetics of RH and its clinical application. *Transfus Clin Biol*. 2006; 13: 4-12.
12. Kormoczi GF, Gassner C, Shao CP, Uchikawa M, Legler TJ. A comprehensive analysis of DEL types: partial DEL individuals are prone to anti-D alloimmunization. *Transfusion*. 2005; 45:1561-7.
13. Shao CP, Maas JH, Su YQ, Kohler M, Legler TJ. Molecular background of Rh D-positive, D-negative, Del and weak D phenotypes in Chinese. *Vox Sang*. 2002; 83:156-161.
14. Sun CF, Chou CS, Lai NC, Wang WT. RHD Gene Polymorphisms among RhD-Negative Chinese in Taiwan. *Vox Sang*. 1998; 75:52-57.
15. Wagner FF, Frohmajer A, Flegel WA. *RHD* positive haplotypes in D negative Europeans. *BMC Genet*. 2001; 2:10.
16. Gassner C, Doescher A, Drnovsek D, Rozman P, Eicher NI, Legler TJ, et al. Presence of RHD in serologically D-, C/E+ individuals: a European multicenter study. *Transfusion*. 2005; 45:527-38.
17. Li Q, Ye LY, Guo ZH, Qian M, Zhu ZY. Study on the molecular background of Del phenotype in Chinese population. *Chin J Med Genet*. 2006; 23: 486-491 (Chinese).
18. Daniels G. *Human Blood Groups*. 1st ed. Oxford: Blackwell Science; 1995.
19. Gupte SC, Kulkarni SS. Incidence of Rh immunization between 1981 and 1992. *The National Medical Journal of India*. 1994; 7:65.
20. Ye LY, Yue D, Wo D, Ding X, Guo S, Li Q, et al. Molecular bases of unexpressed *RHD* alleles in Chinese D-persons. *Transfusion*. 2009; 49:1655-60.
21. Lin IL, Shih MC, Hsieh MH, Liu TC, Chang SE, Lin CL, Chang JG. Molecular basis of weak D in Taiwanese. *Ann Hematol*, 2003; 82: 617-620.
22. Xu Q, Grootkerk-Tax MGHM, Maaskant-van Wijk PA, van der Schoot CE. Systemic analysis and zygosity determination of the *RHD* gene in a D-negative Chinese Han population reveals a novel D-negative *RHD* gene. *Vox Sang*. 2005; 88:35-40.
23. Ye LY, Guo ZH, Li Q, Zhu ZY. Molecular and family analyses of revealed two novel RHD alleles in a survey of a Chinese RhD-negative population. *Vox Sang*. 2007; 92: 242-6.
24. Chen JC, Lin TM, Chen YL, Wang YH, Jin YT, Yue CT. RHD 1227A is an important genetic marker for RhD_{el} individuals. *Am J Clin Pathol*. 2004; 122:193-8.
25. Wang YH, Chen JC, Lin KT, Lee YJ, Yang YF, Lin TM. Detection of RhD_{el} in RhD-negative persons in clinical laboratory. *J Lab Clin Med*. 2005; 146:321-5.
26. Li Q, Hou L, Guo ZH, Ye LY, Yue DQ, Zhu ZY. Molecular basis of the *RHD* gene in blood donors with DEL phenotypes in Shanghai. *Vox Sang*. 2009; 97:139-46.
27. Mak KH, Yan KF, Cheng SS, Yuen MY. Rh phenotypes of Chinese blood donors in Hong Kong, with special reference to weak D antigens. *Transfusion*. 1993; 33: 348-51.

28. Wagner T, Kormoczi GF, Buchta C, Vadon M, Lanzer G, Mayr WR, Legler TJ. Anti-D immunization by DEL red blood cells. *Transfusion*. 2005; 45:520-6.
29. Yasuda H, Ohto H, Sakuma S, Ishikawa Y. [Secondary anti-D immunization by Del red blood cells.](#) *Transfusion*. 2005; 45:1581-4.
30. Luettringhaus TA, Cho D, Ryang DW, Flegel WA. An easy *RHD* genotyping strategy for D- East Asian persons applied to Korean blood donors. *Transfusion*. 2006; 46:2128-37.
31. Garratty G. Do we need to concerned about weak D antigens? *Transfusion*. 2005; 45:1547-51.